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326 A. Ajayi et al Advances in Radiation Oncology: OctobereDecember 2016Methods and materials: An institutional database of 705 nonmetastatic prostate cancer patients
treated with radiation therapy from 2005 through 2013 was used to identify patients undergoing
versus not undergoing pretreatment diagnostic prostate mpMRI. Uni- and multivariable logistic
regression evaluated the relationship of clinical and demographic characteristicswithMRI utilization.
Results: All demographic variables assessed, except the other race category, were signiﬁcantly
associated with MRI utilization (all P < .05), including age (odds ratio [OR], 0.92), black race
(OR, 0.51), poverty (OR, 0.53), closer distance to radiation facility (OR, 1.79), and nonprivate
primary insurance (OR, 0.57) on univariable analysis, while clinical stage T3 (OR, 3.37) was the
only clinical characteristic. On multivariable analysis stratiﬁed by D’Amico risk group, age
remained signiﬁcant across all risk groups, whereas the black versus white racial (OR, 0.21; 95%
conﬁdence interval, 0.08-0.55) and nonprivate versus private insurance type (OR, 0.37; 95%
conﬁdence interval, 0.16-0.86) disparities persisted in the low-risk group. Clinical stage T3
remained associated in the high-risk group. For race speciﬁcally, the percentages of whites,
blacks, and others undergoing MRI in the overall cohort and by risk group were, respectively:
overall, 80% (343/427), 68% (156/231), and 85% (40/47); low risk, 86%, 56%, and 63%;
intermediate risk, 79%, 72%, and 95%; and high risk, 72%, 72%, and 100%.
Conclusions: In this urban, academic center cohort, older patients across all risk groups and black
or nonprivate insurance patients in the low risk group were less likely to undergo staging prostate
MRI scans. Further research should investigate these differences to ensure equitable utilization
across all demographic groups considering the burden of prostate cancer disparities.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Well-documented disparities exist in prostate cancer
incidence, morbidity, and mortality in black versus white
males in the United States.1,2 Identifying appropriate
candidates for active surveillance using only traditional
risk stratiﬁcation parameters (prostate speciﬁc antigen
[PSA], Gleason score, and tumor stage) remains chal-
lenging particularly when considering black race. Recent
analyses from Johns Hopkins found that black men
classiﬁed as having very low-risk prostate cancer, tech-
nically eligible for active surveillance, were more likely to
have adverse pathologic features at the time of radical
prostatectomy,3 as well as larger dominant intraprostatic
lesions (IPLs) with high prevalence of anterior foci.4 A
higher risk of disease progression in black men after
enrollment on active surveillance trials has similarly been
conﬁrmed in other cohorts with larger numbers of black
men.5 There is increased interest in incorporating addi-
tional tools, such as multiparametric magnetic resonance
imaging (mpMRI), into risk stratiﬁcation paradigms given
its ability to detect otherwise occult high-risk features.
Multiparametric MRI with diffusion-weighted imaging
and dynamic contrast enhancement sequences allow for
the identiﬁcation of dominant IPLs.6 Prior diagnostic
literature has demonstrated that IPL characteristics, such
as their apparent diffusion coefﬁcient,7 contrast agent
transfer rate between blood and tissue,8 extracapsular
extension,9 and seminal vesicle invasion,10 are associated
with other known prognostic indicators such as the PSA,
Gleason score, and risk group.9 Pathologic correlationwith prostatectomy specimens has demonstrated the ac-
curacy of these ﬁndings.11 Increasingly, a relationship
between pre-radiation therapy MRI ﬁndings, such as IPL
size, extracapsular extension, and seminal vesicle inva-
sion, and long-term outcomes, such as biochemical
relapse and metastases, has been demonstrated12-15;
however, existing nomograms used in predicting prostate
cancer biochemical relapse after external-beam radiation
therapy, such as the Kattan nomogram16 generally do not
currently include these imaging parameters.
The increasing body of evidence that supports the use
of mpMRI underscores the importance of performing
research to quantify its dissemination. Although prostate
mpMRI may have the potential to reduce prostate cancer
disparities by improving risk stratiﬁcation, it is unclear
how often this technology is used across different clinical
risk and demographic groups. Known cancer health dis-
parities exist in imaging in other malignancies, such as
breast,17 colon,18 and lung19 cancer, but have not been
well explored or documented in prostate cancer, and
health care resource utilization may additionally serve as a
measure of access to care.20 Thus, the aim of our study
was to determine whether disparities exist in mpMRI
utilization across risk groups in men with prostate cancer
undergoing deﬁnitive radiation therapy.
Methods and materials
We conducted an institutional review boardeapproved
retrospective analysis of prostate cancer patients treated
with deﬁnitive external beam radiation therapy with
Table 1 Overall cohort characteristics and comparison of prostate multiparametric MRI vs non-MRI cohort
Variable Characteristic Overall No staging MRI Staging MRI P value
N (%) 705 166 539
Age (y) Mean  SD 67.1  7.9 70.7  7.8 65.9  7.6 <.001
Race White 427 (60.6) 84 (50.6) 343 (63.6) <.001
Black 231 (32.8) 75 (45.2) 156 (28.9)
Other 47 (6.7) 7 (4.2) 40 (7.4)
Poverty No 521 (73.9) 106 (63.9) 415 (77.0) <.001
Yes 184 (26.1) 60 (36.1) 124 (23.0)
Distance (miles) <45 556 (78.9) 142 (85.5) 414 (76.8) .016
45 149 (21.1) 24 (14.5) 125 (23.2)
Primary insurance Private 243 (34.5) 42 (25.3) 201 (37.3) .005
Nonprivate 462 (65.5) 124 (74.7) 338 (62.7)
Treatment year 2005-2007 159 (22.6) 77 (48.4) 82 (51.6) <.001
2008-2009 129 (18.3) 49 (38.0) 80 (62.0)
2010-2013 417 (59.1) 40 (9.6) 377 (90.4)
PSA (ng/mL) Mean  SD 9.6  14.2 10.5  15.3 9.3  13.8 .351
Gleason score 6 290 (41.1) 65 (39.2) 225 (41.7) .439
7 325 (46.1) 75 (45.2) 250 (46.4)
8 52 (7.4) 13 (7.8) 39 (7.2)
9 38 (5.4) 13 (7.8) 25 (4.6)
Clinical T stage T1 502 (71.2) 122 (73.5) 380 (70.5) .006
T2 134 (19.0) 38 (22.9) 96 (17.8)
T3 69 (9.8) 6 (3.6) 63 (11.7)
Risk group High 151 (21.4) 40 (24.1) 111 (20.6) .578
Intermediate 308 (43.7) 68 (41.0) 240 (44.5)
Low 246 (34.9) 58 (34.9) 188 (34.9)
Percent positive biopsy cores Mean  SD 0.4  0.3 0.4  0.3 0.4  0.3 .348
IPSS Mean  SD 7.9  6.5 8.2  6.1 7.8  6.6 .590
IPSS, International Prostate Symptom Score; MRI, magnetic resonance imaging; PSA, prostate-speciﬁc antigen; SD, standard deviation.
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November 2005 and December 2013. Existing medical
databases and electronic medical records were used to
identify all patients (NZ 705) treated with histologically
conﬁrmed, nonmetastatic adenocarcinoma of the prostate.
We collected pretreatment demographic characteristics,
including age, race, socioeconomic status (SES), distance
in miles from home address to the radiation facility, and
primary insurance, primary treating radiation oncologist,
and treatment year. Racial groups included white, black,
Asian, other, and unknown; Asian and unknown were
combined with other for this analysis given their small
numbers in the cohort. As a surrogate for SES, we used
the federal deﬁnition of residing in poverty based on
geocoded census tract.21 Distance was classiﬁed as <45
miles or 45 miles from the radiation treatment facility as
a surrogate for patients residing locally or regionally
versus those traveling more distantly. A total of 95% of
patients received staging MRI at the same facility. Pri-
mary insurance type was classiﬁed as either private or
nonprivate, which included Medicare and Medicaid.
Pretreatment PSA, treatment-recorded clinical tumor
stage (as assessed by digital rectal exam or imaging),
Gleason score, D’Amico risk stratiﬁcation group,22 per-
centage of positive biopsy cores, International ProstateSymptom Score (IPSS), date of prostate cancer diagnosis,
treatment dates, and pretreatment usage of diagnostic
prostate and/or pelvic mpMRI (including T2-weighted,
diffusion-weighted, and/or dynamic contrast-enhanced
sequences, 91% with endorectal coil), were retrospec-
tively recorded through chart review. Patients were
divided into comparison groups based on whether they
did or did not undergo pretreatment diagnostic prostate
mpMRI. Six patients with explicitly recorded contrain-
dications to mpMRI were excluded from the analysis,
leaving 609 patients assessed. During the treatment time
frame, our institution-wide standard practice guideline
encouraged a diagnostic MRI in all-risk prostate cancer
patients without contraindications.Statistical considerations
The primary objective was to compare demographic
and clinical characteristics of prostate cancer patients who
either did or did not undergo pretreatment diagnostic
mpMRI at our institution. Descriptive statistics were
computed for the overall cohort and then MRI versus non-
MRI utilization groups were compared using the c2 test
for categorical variables and the Student t test for
Table 2 Univariable association of demographic and clinical characteristics with staging MRI
Independent variable Characteristic OR (95% CI) P value
Age (y) 0.92 (0.89-0.94) <.001
Race Black vs white 0.51 (0.35-0.73) <.001
Other vs white 1.40 (0.61-3.23) .432
Poverty Yes vs no 0.53 (0.36-0.77) <.001
Distance (miles) 45 vs <45 1.79 (1.11- 2.88) .017
Primary insurance Nonprivate vs private 0.57 (0.39-0.84) .005
Treatment Year 2008-2009 vs 2005-2007 0.43 (0.05 to 2.63) .076
2010-2013 vs 2005-2007 1.40 (0.61-3.23) .432
PSA (ng/mL) 0.99 (0.98-1.01) .354
Gleason score 7 vs 6 0.96 (0.66-1.41) .845
8 vs 6 0.87 (0.44-1.72) .683
9 vs 6 0.56 (0.27-1.15) .112
Clinical T stage T2 vs T1 0.81 (0.53-1.24) .337
T3 vs T1 3.37 (1.42-7.97) .006
Risk group Intermediate vs high 1.27 (0.81-2.00) .296
Low vs high 1.17 (0.73-1.86) .514
Percent positive biopsy cores 0.64 (0.25-1.63) .348
IPSS 0.99 (0.95-1.03) .589
CI, conﬁdence interval; IPSS, International Prostate Symptom Score; MRI, magnetic resonance imaging; OR, odds ratio; PSA, prostate-speciﬁc
antigen.
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positive biopsy cores, and IPSS were analyzed as
continuous variables, and the remainder as categorical.
All P values were 2-sided. Univariable logistic regression
was used to evaluate the relationship of clinical and de-
mographic characteristics with MRI utilization as the
outcome variable. Multivariable logistic regression
models were constructed using variables signiﬁcant in the
univariable analysis. Multivariable analysis was stratiﬁed
by risk group to best approximate clinical practice and
decision making at the common point of MRI utilization.
Odds ratios (OR) were reported with associated 95%
conﬁdence intervals (CI). A P value <.05 was considered
statistically signiﬁcant. Analyses were conducted using
either STATA/MP 13 (College Station, TX) or SAS,
version 9.4 (Cary, NC).Results
Table 1 shows the overall cohort and comparison of
characteristics for those who underwent MRI compared
with those who did not. Demographically, patients who
did not undergo MRI were signiﬁcantly older (mean age
67 vs 71), and more likely to reside in poverty (36% vs
23%), live closer to the facility (<45 miles), have non-
private primary insurance, and be of black race (all P
values < .05). The percentages of whites, blacks, and the
other race group undergoing MRI were 80% (343/427),
68% (156/231), and 85% (40/47), respectively. There was
also increasing MRI utilization over time. Regarding
clinical characteristics, patients undergoing MRI weremore likely to have clinical stage T3 disease (11.7% vs
3.6%); the cohorts did not differ by PSA (mean 10.5 vs
9.3), Gleason score, risk group, percentage positive bi-
opsy cores, or IPSS, respectively, for the cohort that had
an MRI versus the cohort that did not.
On univariable logistic regression (Table 2), all de-
mographic variables assessed, except for the other race
category, were associated with MRI utilization, including
age (OR, 0.92; 95% CI, 0.89-0.94; P < .05), black race
(OR, 0.51, 0.35, 0.73; P < .05), poverty (OR, 0.53, 0.36,
0.77; P < .05), distance (OR, 1.79; 1.11, 2.88; P < .05),
and primary insurance type (OR, 0.57, 0.39, 0.84;
P < .05). Only clinical stage T3 (OR, 3.37, 1.42, 7.97;
P < .05) was associated with MRI utilization, whereas
treatment year and the other clinical characteristics
assesseddPSA, Gleason score, clinical stage, risk group,
percent positive cores, and IPSSdwere not.
The results of the multivariable logistic regression
stratiﬁed by risk group are shown in Table 3. Age was
associated with MRI utilization in all risk groups. Black
versus white race (OR, 0.21, 0.08, 0.55; P < .05) and
nonprivate versus private insurance (OR, 0.37, 0.16, 0.86;
P < .05) were associated with MRI utilization in the low-
risk group (Fig 2). Clinical stage T3 remained associated
with MRI utilization in the high-risk group.
Figure 1 shows MRI utilization by risk group and the
variables signiﬁcant on multivariable analysisdage, race,
and insurance type. For age (Fig 1A), the percentages of
men younger than age 65 compared with 65 undergoing
MRI in the low-, intermediate-, and high-risk groups
were, respectively, 91% versus 67%, 86% versus 73%,
and 86% versus 68% (all P < .05). For race (Fig 1B), the
Table 3 Risk group stratiﬁed multivariable association of demographic and clinical characteristics with staging MRI
Risk group Variable Characteristic OR (95% CI) P value
Low Age 0.89 (0.84-0.94) <.001
Race Black vs white 0.21 (0.08-0.55) .001
Other vs white 0.22 (0.06-0.77) .018
Poverty Yes vs no 0.64 (0.25-1.64) .353
Primary insurance Nonprivate vs private 0.37 (0.16-0.86) .020
Distance (miles) 45 vs <45 1.28 (0.48-3.44) .623
Clinical T stage T2 vs T1 0.51 (0.19-1.40) .193
Intermediate Age 0.94 (0.90-0.97) <.001
Race Black vs white 0.71 (0.29-1.73) .454
Other vs white 5.57 (0.71-43.8) .103
Poverty Yes vs no 0.98 (0.39-2.47) .973
Primary insurance Nonprivate vs private 1.03 (0.55-1.93) .930
Distance (miles) 45 vs <45 1.26 (0.59, 2.71) .551
Clinical T stage T2 vs T1 1.38 (0.66-2.85) .390
High Age 0.93 (0.88-0.98) .013
Race Black vs white 0.99 (0.34-2.87) .989
Other vs white NE NE
Poverty Yes vs no 0.92 (0.30-2.79) .879
Primary insurance Nonprivate vs private 0.79 (0.31-2.01) .623
Distance (miles) 45 vs <45 1.03 (0.31-3.42) .967
Clinical T stage T2 vs T1 0.52 (0.20-1.34) .176
T3 vs T1 3.75 (1.25-11.3) .019
CI, conﬁdence interval; MRI, magnetic resonance imaging; NE, not estimable due to small number of patients; OR, odds ratio.
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86% and 56%, in the low-risk group, 79% and72% in the
intermediate-risk group, and 72% and 72% in the high-
risk group, respectively. The percentages of patients
with private insurance compared to nonprivate (Fig 1C)
undergoing MRI in the low-, intermediate-, and high-risk
groups were, respectively, 87% versus 71% (P < .05),
80% versus 76%, and 80% versus 70%.Discussion
In this urban, academic center cohort of nonmetastatic
prostate cancer patients undergoing deﬁnitive radiation
therapy, we explored whether clinical and demographic
disparities exist in mpMRI utilization. We found that
demographic characteristics, including age, race, poverty,
and insurance type were associated with mpMRI utiliza-
tion, whereas most clinical parameters, including PSA,
Gleason score, and IPSS, were not. Patients not under-
going mpMRI were older and more likely to reside in
poverty, live closer to the facility, have nonprivate pri-
mary insurance, and be of black race, indicating that de-
mographic and not clinical characteristics most inﬂuenced
mpMRI utilization. On multivariable analysis, age
remained signiﬁcant across all risk groups, and race and
insurance type persisted only in the low-risk group.
Current National Cancer Comprehensive Network
(NCCN) guidelines recommend cross-sectional imagingfor all high-risk patients and also indicate that mpMRI
may be used to risk-stratify patients who are considering
active surveillance.23 American College of Radiology
guidelines similarly recommend mpMRI in intermediate-
and high-risk patients and indicate that MRI scans may be
appropriate in low-risk patients considering active sur-
veillance.24 Despite these staging guidelines and MRI’s
increasing role in aiding treatment selection and surgical
and radiation planning,25 several studies have reported
MRI use that is discordant with historical and present
guidelines, including overutilization among low-risk pa-
tients and underutilization among high-risk patients.26,27
Although we do not postulate a “correct” utilization
rate, in our study we did interestingly ﬁnd disparate uti-
lization trends by age, insurance type, and race. For race
speciﬁcally, blacks (Fig 1) and the other categoryd
patients that were neither white nor blackdwere signiﬁ-
cantly less likely to undergo mpMRI than whites in the
low-risk group, but there were no signiﬁcant differences
in the intermediate- and high-risk groups, reassuringly
suggesting equitable utilization by race in these more
advanced risk groups. However, considering the emerging
evidence for mpMRI in active surveillance28 in the
context of racial disparities in prostate cancer, a plausible
opportunity emerges to use this technology to improve
staging in black men and positively affect management
decisions. The racial disparity observed in our study is
therefore very concerning, given that black men in the
low-risk group who have been found to have high rates of
Figure 1 Percentage prostate MRI utilization by (A) age, (B) race, and (C) insurance type and prostate cancer risk groups. *Rep-
resents signiﬁcant difference; error bars represent the 95% conﬁdence interval. Int, intermediate.
Figure 2 Plot of adjusted* (dashed line) and unadjusted (solid
line) odds ratios of prostate magnetic resonance imaging utili-
zation for black vs white men from the multivariable analysis
stratiﬁed by risk-group. *Adjusted for age, poverty, primary
insurance type, distance, and clinical stage.
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the additional information offered by the mpMRI. As this
was ultimately a treatment cohort, it would be important
to verify the analysis in an active surveillance cohort to
determine whether the utilization disparities pervade.
Racial disparities in imaging utilization have been
well-described in other malignancies,17-19 but only to a
limited extent in prostate cancer. An analysis from the
Surveillance, Epidemiology and End Results-Medicare
linked database evaluating staging workup before and
after implementation of NCCN, American Urological
Association, and American College of Radiology guide-
lines in 96,986 men with incident prostate cancer from
1991 to 1994 compared with 1995 to 1999 found that, of
men who met guideline criteria for staging, black men
were less likely to undergo bone scan and pelvic imaging
than white men diagnosed from 1991 to 1994, but this
racial difference was not seen from 1995 to 1999, sug-
gesting historical improvements in disparate imaging
trends. This parity was not noted in our study for patients
Advances in Radiation Oncology: OctobereDecember 2016 Prostate MRI disparities 331in the low-risk group. In contrast, a more recent Sur-
veillance, Epidemiology and End Results-Medicare
analysis of prostate cancer patients diagnosed between
2004 and 2007 found that race was signiﬁcantly associ-
ated with nonadherence to imaging guidelines on multi-
variable models, with bone scan and pelvic computed
tomography (CT)/MRI overuse associated with non-white
race (reference, white race).29 This same study did,
however, ﬁnd underuse of bone scan and pelvic CT/MRI
associated with patient age >79 years (reference age, 66-
69), consistent with the age disparity found in our study.
The age disparity seen in this previous report as well as
our own study across risk groups was expectedly
consistent with numerous studies in other malignancies
demonstrating that older patients tend to have less
rigorous staging workup than younger patients.30
The reason behind these age and racial disparities is
likely multifactorial, including SES, insurance status,
provider biases, and access to care. However, in a single
academic institution experience with standard therapeutic
regimens, one might expect the impact of these de-
mographic factors to be lessened or eliminated, as has
been shown in a secondary analysis of black men enrolled
on prostate radiation therapy cooperative group trials.31
This was not the case in our study. Finally, we did also
ﬁnd that private insurance type was associated with
mpMRI utilization in the low-risk group. Being uninsured
or having nonprivate insurance, such as Medicaid, has
been consistently associated with poor health out-
comes.32,33 Furthermore, patient insurance status has been
shown to affect clinical decisions, both directly (ie, if the
patient cannot afford the service) and indirectly by
contributing to provider biases and preconceived notions
that affect decision-making.32,34,35
A limitation of our study is that it represents a radiation
therapy cohort and whether such disparities in mpMRI
utilization exist in other prostate cancer management co-
horts (eg, active surveillance, surgical, metastatic) re-
mains to be explored. Additionally, we did not record
whether patients not obtaining mpMRI had alternative
cross-sectional imaging, such as CT, given that mpMRI is
superior to CT in identifying intraprostatic lesions and
adverse tumor characteristics. Indeed, the association of
clinical T3 stage on multivariable analysis and MRI uti-
lization in our study potentially speaks to the superior
local staging and anticipated tumor upstaging by mpMRI.
We also intentionally excluded provider-level character-
istics because we were retrospectively unable to capture
the “true” ordering physician and it is unclear (however
unlikely) that disparate patterns of mpMRI utilization may
have systematically reﬂected different referral origins (ie,
radiation oncology vs urology vs medical oncology vs
primary care), despite institution wide preference for MRI
as baseline staging. Similarly, it is unknown whether
providers may have ordered the MRI scans, but they were
not obtained by the patient due to ﬁnancial, psychosocial,logistical, and other barriers. We did not exclude patients
with explicit contraindication to MRI (3 of 166 not un-
dergoing MRI) given the potential likelihood that other
patients had absolute and relative contraindications that
were not documented in the available records over the
study period; it is uncertain how this may differ by de-
mographics or risk group in this prostate cancer radiation
therapy cohort. Regarding insurance status, because pri-
mary insurance type was recorded at the time of treat-
ment, at which time all patients would have acquired
insurance, insurance status at time of diagnosis was un-
known, which may or may not have inﬂuenced mpMRI
utilization. However, there is evidence that patients with
either Medicaid or who are uninsured have similarly
poorer cancer outcomes.36,37 Lastly, as a surrogate for
SES, we used the federal deﬁnition of residing in poverty
(>20%) based on geocoded census tract coded as a binary
outcome, which differed signiﬁcantly at baseline, but not
in multivariable analysis. Similar results were seen with
the percent residing in poverty analyzed as a continuous
variable (results not shown). Nonetheless, other SES
surrogates such as median income or education level
might have yielded an association with SES and helped to
parse the complex association between race and SES.Conclusions
In this urban, academic center cohort, prostate cancer
patients that were older, regardless of risk group, and
that were black or with nonprivate insurance in the low-
risk group, were less likely to undergo staging MRI.
Collectively, these data raise areas for further practice
review, analysis, and improvement, and should be
undertaken on a wider scale as we embrace active sur-
veillance, given the dearth of data on the safety and
applicability of this strategy to black and older men.
Given the known disproportionate burden of prostate
cancer morbidity and mortality, further research should
investigate whether MRI can help reduce prostate cancer
disparities and is equitably used across all demographic
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